Ultragenyx Logo

Physiomimic Technology™: discover the benefits of amino acids' physiological absorption in PKU

The absorption kinetics of free amino acids (AAs) can affect the metabolic management of people with PKU. Indeed, free amino acids have a limited biological efficacy, due to the fact they do not need to be digested, thus leading to a rapid absorption and a higher concentration in blood, exceeding the ability of the organism to incorporate them into new proteins.Physiomimic Technology™ consists of a multi-step process of granulation and coating of AAs which provides prolonged release and physiological absorption of AAs, similar to proteins contained in natural foods.In the same way, Physiomimic Technology™ masks the unpleasant AA taste and odour, while preventing aftertaste and bad breath.Based on available evidence, APR formulated PKU GOLIKE, the first Phe-free protein substitute that provides a more physiological absorption of amino acids, in the direction of proteins contained in natural food. PKU GOLIKE aims to improve metabolic management and provide potential health benefits and quality of life in the long term.

PKU GOLIKE: the new Phe-free AA mix providing physiological absorption for PKU

PKU GOLIKE is an innovative Phenylalanine-free amino acid mix in granules, for the treatment of Phenylketonuria (PKU).
The patented Physiomimic Technology™ provides coated granules that support prolonged release and physiological absorption of amino acids, while masking AA taste and odour, preventing aftertaste and bad breath. The format in granules allows to mask unpleasant organoleptic features of amino acids because they remain intact during consumption of PKU GOLIKE, dissolving only during the digestion process.
PKU GOLIKE is versatile and can be consumed in different ways, depending on the patient’s preference. The format in granules makes it ideal to be added to creamy food and thick drinks, ensuring the original flavour is not altered. For those who prefer drinking it in just a few sips, PKU GOLIKE can be consumed in combination with GOLIKE Shake & Drink: a practical solution to make the intake of granules as easy as drinking a glass of water!

Get in touch

Serena Castelnovo
Serena CastelnovoMarketing Manager Metabolics
    Silvia Galatello
    Silvia GalatelloProduct Manager Metabolics
      Antonio Valverde Corcho
      Antonio Valverde CorchoKey Account Manager B2B
        Patrizia Marzorati, PhDHead of Medical Affairs
          Alessia BettinelliDirector of Marketing & Sales Metabolics

            About APR

            APR is an independent pharma company headquartered in Switzerland with subsidiaries in Italy and Germany focused, for more than 25 years, in the development and commercialisation of products intended to improve the quality of life of patients and families affected with rare or debilitating diseases.

            APR leverages many years of experience in developing patented drug delivery technologies, which are then applied to develop innovative therapeutic solutions.

            APR’s portfolio includes products for the treatment of rare or niche diseases which are commercialised in about 50 countries worldwide either directly through its subsidiaries as well as indirectly through distribution agreements with selected partners.

            APR believes that a tireless effort in the research represents the fundamental pillar of the future therapeutic solutions and, for this reason, the pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: cancer supportive care,  skin rare diseases and inherited metabolic recessive diseases, among which Phenylketonuria (PKU).

            PKU GOLIKE is APR’s first Food for Special Medical Purposes for the dietary management of PKU, consisting of a Phenylalanine-free mix in granules.

            Thanks to APR’s patented Physiomimic Technology, PKU GOLIKE provides prolonged release and physiological absorption of amino acids in line with intact proteins, while masking their unpleasant taste and odour, as well as preventing aftertaste and halitosis.

            PKU GOLIKE, currently available in several countries in Europe, aims to improve quality of life and provide potential health benefits for people living and dealing with PKU.